What is the duration of action of Methylergonovine (Methergine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

The plasma level decline was biphasic with a mean elimination half-life of 3. 39 hours (range 1.5 to 12.7 hours). The duration of action of Methergine (methylergonovine) is related to its elimination half-life, which is approximately 3.39 hours on average, but can range from 1.5 to 12.7 hours 1.

  • The onset of action is immediate after intravenous administration, 2 to 5 minutes after intramuscular administration, and 5 to 10 minutes after oral administration.
  • The duration of action is not explicitly stated, but based on the elimination half-life, it can be inferred that the effects of Methergine may last for several hours.

From the Research

Methergine (methylergonovine maleate) has a duration of action of approximately 3 to 6 hours when administered orally, and about 45 minutes to 3 hours when given intramuscularly or intravenously. This uterotonic medication is primarily used to prevent and treat postpartum hemorrhage by causing sustained uterine contractions. The relatively short duration necessitates repeated dosing when used for ongoing management of uterine atony. Typical oral dosing is 0.2 mg every 6-8 hours for up to 7 days postpartum, while parenteral administration is usually 0.2 mg intramuscularly every 2-4 hours for a maximum of 5 doses. Methergine works by directly stimulating smooth muscle receptors in the uterus, leading to increased tone, rate, and amplitude of rhythmic contractions. This action helps compress blood vessels and reduce bleeding. Patients should be monitored for hypertension during treatment as Methergine can cause significant vasoconstriction, and it is contraindicated in patients with hypertension and preeclampsia.

Some key points to consider when using Methergine include:

  • The need for repeated dosing due to its relatively short duration of action
  • The importance of monitoring for hypertension and other potential side effects
  • The contraindication in patients with hypertension and preeclampsia
  • The potential for additive or synergistic effects when used in combination with other uterotonics, such as oxytocin 2
  • The comparison of Methergine with other uterotonics, such as carbetocin, misoprostol, and carboprost, in terms of efficacy and safety 3

It is essential to weigh the benefits and risks of Methergine and other uterotonics in the prevention and treatment of postpartum hemorrhage, considering the most recent and highest-quality evidence available 3.

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.